[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer

Oncogene volume 37, pages 5939–5951 (2018)Cite this article

Subjects

Abstract

As one of the primary members of SWI/SNF chromatin remodeling complexes, ARID1A contains frequent loss-of-function mutations in many types of cancers. However, the molecular mechanisms underlying ARID1A deficiency in cancer biology remain to be investigated. Using breast cancer as a model, we report that silencing ARID1A significantly increased cellular proliferation and migration. Mechanistically, primarily functioning as a transcriptional repressor, loss of ARID1A profoundly alters histone modifications and the transcriptome. Notably, ARID1A inhibited the expression of a long non-coding RNA, UCA1, by regulating chromatin access of the transcription factor CEBPα. Restoration experiments showed that UCA1 mediates the functions of ARID1A that induces loss of cellular proliferation and migration. Together, our findings characterize ARID1A as a key tumor-suppressor gene in breast cancer through cooperation with CEBPα, and loss-of-function mutations of ARID1A activates UCA1.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Alteri R, Bertaut T, Brinton LA, Fedewa S, Freedman RA, Gansler T, et al. Breast Cancer Facts and Figures 2015-2016. Atlanta: American Cancer Society, Inc.; 2015.

    Google Scholar 

  2. Wilson BG, Roberts CW. SWI/SNF nucleosome remodelers and cancer. Nat Rev Cancer. 2011;11:481–92.

    Article  CAS  Google Scholar 

  3. Cho HD, Lee JE, Jung HY, Oh MH, Lee JH, Jang SH, et al. Loss of tumor suppressor ARID1A protein expression correlates with poor prognosis in patients with primary breast cancer. J Breast Cancer. 2015;18:339–46.

    Article  Google Scholar 

  4. Wiegand KC, Shah SP, AI-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532–43.

    Article  CAS  Google Scholar 

  5. Jones S, Wang TL, Shih IEM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228–31.

    Article  CAS  Google Scholar 

  6. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol. 2011;224:328–33.

    Article  CAS  Google Scholar 

  7. Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, et al. ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol Rep. 2016;35:607–13.

    Article  CAS  Google Scholar 

  8. Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH, et al. Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol. 2013;44:1365–74.

    Article  CAS  Google Scholar 

  9. Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, Birnbaum DJ, et al. Mutations and deletions of ARID1A in breast tumors. Oncogene. 2012;31:4255–6.

    Article  CAS  Google Scholar 

  10. Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3:35–43.

    Article  CAS  Google Scholar 

  11. Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol. 2012;5:642–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H, et al. Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol. 2012;36:288–93.

    Article  CAS  Google Scholar 

  13. Zhao J, Liu C, Zhao Z. ARID1A: a potential prognostic factor for breast cancer. Tumour Biol. 2014;35:4813–9.

    Article  CAS  Google Scholar 

  14. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet. 2017;49:296–302.

    Article  CAS  Google Scholar 

  15. Guan B, Gao M, Wu CH, Wang TL, Shih leM. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia. 2012;14:986–93.

    Article  CAS  Google Scholar 

  16. Guan B, Wang TL, Shih leM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71:6718–27.

    Article  CAS  Google Scholar 

  17. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5:752–67.

    Article  CAS  Google Scholar 

  18. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT- inhibition. Oncotarget. 2014;5:5295–303.

    Article  Google Scholar 

  19. Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression ofp27 (Kip1). Cell Death Dis. 2014;5:e1008.

    Article  CAS  Google Scholar 

  20. Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, et al. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015;6:18534–44.

    Article  Google Scholar 

  21. Wang Z, Wang X, Zhang D, Yu Y, Cai L, Zhang C. Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer. Tumour Biol. 2017;39:1010428317709990.

    PubMed  Google Scholar 

  22. Wang ZQ, Cai Q, Hu L, He CY, Li JF, Quan ZW, et al. Long noncoding RNA UCA1 induced by SP1 promotes cell proliferation via recruiting EZH2 and activating AKT pathway in gastric cancer. Cell Death Dis. 2017;8:e2839.

    Article  CAS  Google Scholar 

  23. Block K, Gorin Y, New DD, Eid A, Chelmicki T, Reed A, et al. The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol. 2010;176:2447–55.

    Article  CAS  Google Scholar 

  24. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013;39:1095–107.

    Article  CAS  Google Scholar 

  25. Sun X, Chuang JC, Kanchwala M, Wu L, Celen C, Li L, et al. Suppression of the SWI/SNF component ARID1A promotes mammalian regeneration. Cell Stem Cell. 2016;18:456–66.

    Article  CAS  Google Scholar 

  26. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O’Driscoll L, et al. Correlating transcriptional networks to breast cancer survival: a large-scale co-expression analysis. Carcinogenesis. 2013;34:2300–8.

    Article  CAS  Google Scholar 

  27. Priam P, Krasteva V, Rousseau P, D’Angelo G, Gaboury L, Sauvageau G, et al. SMARCD2 subunit of SWI/SNF chromatin-remodeling complexes mediates granulopoiesis through a CEBPε dependent mechanism. Nat Genet. 2017;49:753–64.

    Article  CAS  Google Scholar 

  28. Müller C, Calkhoven CF, Sha X, Leutz A. The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest. J Biol Chem. 2004;279:7353–8.

    Article  Google Scholar 

  29. Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene. 2012;31:2090–100.

    Article  CAS  Google Scholar 

  30. Takao C, Morikawa A, Ohkubo H, Kito Y, Saigo C, Sakuratani T, et al. Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer. J Cancer. 2017;8:1–8.

    Article  CAS  Google Scholar 

  31. Zhang L, Cao X, Zhang L, Zhang X, Sheng H, Tao K. UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol. 2016;77:629–34.

    Article  CAS  Google Scholar 

  32. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014;281:1750–8.

    Article  CAS  Google Scholar 

  33. Wang H, Guan Z, He K, Qian J, Cao J, Teng L. Lnc RNA UCA1 in anti-cancer drug resistance. Oncotarget. 2017;8:64638–50.

    PubMed  PubMed Central  Google Scholar 

  34. Li X, Wu Y, Liu A, Tang X. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop. Tumor Biol. 2016;37:14733–43.

    Article  CAS  Google Scholar 

  35. Yuan J, Jiang YY, Mayakonda A, Huang M, Ding LW, Lin H, et al. Super-enhancers promoter transcriptional dysregulation in nasopharyngeal carcinoma. Cancer Res.2017;77:6614–26.

    Article  CAS  Google Scholar 

  36. Guo X, Dong Y, Yin S, Zhao C, Huo Y, Fan L, et al. Patulin induces pro-survival functions via autophagy inhibition and p62 accumulation. Cell Death Dis. 2013;4:e822.

    Article  CAS  Google Scholar 

  37. Lin DC, Dinh HQ, Xie JJ, Mayakonda A, Silva TC, Jiang YY, et al. Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas. Gut. 2017. https://doi.org/10.1136/gutjnl-2017-314607.

    Article  Google Scholar 

Download references

Acknowledgements

ARID1A shRNA and ARID1A CRISPR-Cas9 plasmid are gifts from Vikas Madan, Cancer Science Institute of Singapore; pCDH-CMV-UCA1-EF1-copGFP is a gift from Yin-Yuan Mo, University of Mississippi Medical Center. This research was supported by the National Research Foundation Singapore under its Singapore Translational Research Investigator Award (NMRC/STaR/0021/2014) and administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC), the NMRC Centre Grant awarded to National University Cancer Institute, the National Research Foundation Singapore, and the Singapore Ministry of Education under its Research Centers of Excellence initiatives to H.P.K. This study was additionally funded by the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education’s Tier 3 grants (MOE2014-T3-1-006). D.-C.L was supported by Tower Cancer Research Foundation. Part research was supported by National Natural Science Foundation of China (NSFC, 31401594, to X.G.) and the generous support of Michele and Ted Kaplan Family Fund and the Tower Foundation.

Author information

Authors and Affiliations

  1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

    Xiao Guo, Yin Zhang, Le-Hang Lin & Dong Yin

  2. Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Xiao Guo, Saadiya Zia, Sigal Gery, De-Chen Lin & H. Phillip Koeffler

  3. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore

    Anand Mayakonda, Vikas Madan, Ling-Wen Ding & H. Phillip Koeffler

  4. Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA

    Jeffrey W. Tyner

  5. Department of Medicine, College of Medicine and Health, Lishui University, Zhejiang, China

    Wu Zhou

  6. National University Cancer Institute, National University Hospital, Singapore, Singapore

    H. Phillip Koeffler

Authors
  1. Xiao Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anand Mayakonda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vikas Madan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling-Wen Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Le-Hang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Saadiya Zia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sigal Gery
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeffrey W. Tyner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dong Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. De-Chen Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H. Phillip Koeffler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiao Guo or De-Chen Lin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, X., Zhang, Y., Mayakonda, A. et al. ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer. Oncogene 37, 5939–5951 (2018). https://doi.org/10.1038/s41388-018-0371-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-018-0371-4

Search

Advanced search

Quick links